Resmetirom Drug Asset Due Diligence Report 2026

This Resmetirom Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Resmetirom can convert its Small molecule drug profile and THR-β biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Resmetirom (query alias: resmetirom)
Modality / target	Small molecule drug; THR-β; THR-β agonists
Highest global status	Approved
Originator	F. Hoffmann-La Roche Ltd.
Active developers	Madrigal Pharmaceuticals, Inc., Madrigal Pharmaceuticals EU Ltd., Madrigal Ltd.

The MCP disease footprint includes Fibrosis, Liver, Metabolic Dysfunction Associated Steatohepatitis, Liver Cirrhosis. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07249788	Phase 4	Recruiting	165	FIB-4 and CAP score/LSM on fibroscan
NCT07680478	Phase 4	Not yet recruiting	120	MRI-PDFF change
NCT07335601	Phase 2	Recruiting	120	Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Self-Reported Cognitive Function in Metabolic Dysfunction–associated Steatotic Liver Disease and Metabolic Dysfunction–associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials

Phase 2/3; n=2243; evaluation: Positive. Reported fields: Cognitive Function Self-Report score(24-week) = -2.7 Point ( -4.7 to -0.6); Cognitive Function Self-Report score(24-week) = -3.0 Point ( -4.9 to -1.0)

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis

Phase 2; n=125; evaluation: not stated. Reported fields: Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)(Least Squares Mean) = -10.4 percent change (Standard Error, 4.3); Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)(Least Squares Mean): Mean Difference (Net) = -22.5(95% CI, -32.9 to -12.2), P-Value = <0.0001; Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)(Least Squares Mean): Mean Difference (Net) = -22.5(95% CI, -32.9 to -12.2), P-Value = <0.0001

A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo Controlled Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia

Phase 2; n=116; evaluation: not stated. Reported fields: Mean Percent Change in LDL-C From Baseline To Week 12(Least Squares Mean) = 8.2 percent change (Standard Error, 3.71); Mean Percent Change in LDL-C From Baseline To Week 12(Least Squares Mean): Mean Difference (Net) = -18.8(95% CI, -27.8 to -9.8), P-Value = <0.0001; Mean Percent Change in LDL-C From Baseline To Week 12(Least Squares Mean): Mean Difference (Net) = -18.8(95% CI, -27.8 to -9.8), P-Value = <0.0001

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Resmetirom addresses Fibrosis, Liver, Metabolic Dysfunction Associated Steatohepatitis, Liver Cirrhosis. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 3 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-12-17	Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program	Approved	Financial terms not disclosed
2011-09-14	License agreement signed between YM BioSciences Inc. and the University of Manitoba and the Manitoba Cancer Treatment and Research Foundation	Phase 1	Financial terms not disclosed
2008-12-23	VIA Pharmaceuticals Licenses Drug Candidates from Roche to Expand Cardiovascular Pipeline to Include Metabolic Disease	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Preparation method of Resmetirom key intermediate”. The milestone feed surfaced a patent-application signal described as “Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension”. The milestone feed surfaced a patent-application signal described as “THR-beta modulators, alone or in combination with GLP-1r\GIPR\GCGR modulators for the treatment of metabolic diseases and alopecia areata diseases”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO